WANBURY LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 145 INR | +1.50% |
|
-2.49% | +9.89% |
| Apr. 01 | Wanbury Limited Announces Retirement of Narinder Kumar Puri as Independent Director | CI |
| Feb. 21 | Wanbury Limited Announces Retirement of Pallavi Prakash Shedge as Independent Director | CI |
| Sales 2022 | 5.11B 61.28M | Sales 2023 | 5B 59.9M | Capitalization | 1.22B 14.63M |
|---|---|---|---|---|---|
| Net income 2022 | 815M 9.77M | Net income 2023 | -104M -1.25M | EV / Sales 2022 | 0.66 x |
| Net Debt 2022 | 583M 6.99M | Net Debt 2023 | 764M 9.16M | EV / Sales 2023 | 0.4 x |
| P/E ratio 2022 |
3.37
x | P/E ratio 2023 |
-11.7
x | Employees | 1,582 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 43.43% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.50% | ||
| 1 week | -2.49% | ||
| Current month | -2.45% | ||
| 1 month | +2.44% | ||
| 3 months | -2.88% | ||
| 6 months | +27.13% | ||
| Current year | +9.89% |
1 week
132.70
150.80
1 month
132.55174.35
Current year
122.10177.40
1 year
46.56177.40
3 years
33.05177.40
5 years
10.90177.40
10 years
10.90177.40
| Managers | Title | Age | Since |
|---|---|---|---|
Vinod Verma
DFI | Director of Finance/CFO | - | 16-04-21 |
| Compliance Officer | - | 15-08-19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 65 | 01-01-22 | |
Anupama Vaidya
BRD | Director/Board Member | 52 | 22-03-16 |
| Director/Board Member | - | Nov. 17 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-06 | 145 | +1.50% | 7,721 |
| 24-06-05 | 142.9 | +2.33% | 17,650 |
| 24-06-04 | 139.6 | -5.00% | 10,415 |
| 24-06-03 | 147 | -1.14% | 16,822 |
| 24-05-31 | 148.7 | -0.03% | 6,443 |
Delayed Quote Bombay S.E., June 06, 2024 at 06:00 am EDT
More quotes
Wanbury Limited is an India-based pharmaceutical company. The Company is engaged in the business of pharmaceutical and related activities, including research. The Company operates through two divisions: the Active Pharmaceutical Ingredients (API) Business and the Domestic Formulations Business. The Company, through the Active Pharmaceutical Ingredients (API) Business, provides Metformin and Sertraline. Metformin is used for the treatment for type 2 diabetes and Sertraline is an anti-depressant. It has approximately 13 API products. It manufactures Metformin with over 8500 tons per year. Its products include Metformin HCL, Metformin DC/SR, Sertraline, Diphenhydramine, Mefenamic Acid, Glucosamine, Methoxsalen and Paroxetine. The Company's subsidiaries include Wanbury Holdings B. V. (Netherland), Wanbury Global FZE (UAE), Ningxia Wanbury Fine Chemicals Co. Ltd. (China) and Cantabria Pharma S. L. (Spain).
Sector
Pharmaceuticals
Calendar
2024-08-07
- Q1 2025 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +9.89% | 56.11M | |
| +16.93% | 42.79B | |
| +22.16% | 22.81B | |
| +16.96% | 15.04B | |
| +18.51% | 14.49B | |
| +51.63% | 12.65B | |
| -0.05% | 6.79B | |
| -11.72% | 6.74B | |
| -8.87% | 5.73B | |
| +14.27% | 5.47B |
- Stock Market
- Equities
- WANBURY Stock
